Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.

MLA

Le, Dung T., et al. “Safety and Survival with GVAX Pancreas Prime and Listeria Monocytogenes-Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 33, no. 12, Apr. 2015, pp. 1325–33. EBSCOhost, https://doi.org/10.1200/JCO.2014.57.4244.

APA

Le, D. T., Wang-Gillam, A., Picozzi, V., Greten, T. F., Crocenzi, T., Springett, G., Morse, M., Zeh, H., Cohen, D., Fine, R. L., Onners, B., Uram, J. N., Laheru, D. A., Lutz, E. R., Solt, S., Murphy, A. L., Skoble, J., Lemmens, E., Grous, J., … Jaffee, E. M. (2015). Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 33(12), 1325–1333. https://doi.org/10.1200/JCO.2014.57.4244

Chicago

Le, Dung T, Andrea Wang-Gillam, Vincent Picozzi, Tim F Greten, Todd Crocenzi, Gregory Springett, Michael Morse, et al. 2015. “Safety and Survival with GVAX Pancreas Prime and Listeria Monocytogenes-Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 33 (12): 1325–33. doi:10.1200/JCO.2014.57.4244.